Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Cir- culation. 1998;98:734 41. 266. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 267. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/ IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895 903. 268. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment el- evation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 269. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolim- us-eluting or uncoated stents for acute myocardial infarction: the MUL- TISTRATEGY randomized trial. JAMA. 2008;299:1788 99. 270. Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol. 2010;56:470 5. O Gara et al 2013 ACCF/AHA STEMI Guideline e409 271. Ellis SG, Tendera M, de Belder MA, et al. 1-Year survival in a random- ized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2:909 16. 272. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary in- tervention of acute ST-segment elevation myocardial infarction: a meta- analysis. JAMA. 2004;292:362 6. 273. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517 24. 274. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarc- tion: quantitative review of randomised trials. Lancet. 2006;367:579 88. Erratum in: Lancet. 2006;367:1656. 275. Van t Hof AWJ, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergo- ing primary angioplasty (On-TIME 2): a multicentre, double-blind, ran- domised controlled trial. Lancet. 2008;372:537 46. 276. El Khoury C, Dubien P-Y, Mercier C, et al. Prehospital high-dose tirofi- ban in patients undergoing primary percutaneous intervention: the AGIR- 2 study. Arch Cardiovasc Dis. 2010;103:285 92. 277. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibi- tors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient s data meta-analysis. J Thromb Haemost. 2011;9:2361 70. 278. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percu- taneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933 40. 279. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardio- vasc Interv. 2004;62:186 92. 280. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol. 2005;105:250 5. 281. Iversen A, Galatius S, Jensen JS. The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percutane- ous coronary intervention: intravenous versus intracoronary. Curr Car- diol Rev. 2008;4:293 9. 282. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoro- nary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31 4. 283. W hrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable an- gina undergoing coronary angioplasty. Circulation. 2003;107:1840 3. 284. Bertrand OF, Rod s-Cabau J, Larose E, et al. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction un- dergoing transradial primary percutaneous coronary intervention: a two- by-two factorial placebo-controlled randomized study. Am J Cardiol. 2010;105:1520 7. 285. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354 62. 286. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymor- phism in young patients treated with clopidogrel after myocardial infarc- tion: a cohort study. Lancet. 2009;373:309 17. 287. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916 22. 288. Giusti B, GoriAM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806 11. 289. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clini- cal alert: approaches to the FDA boxed warning : a report of the Ameri- can College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537 57. 290. Par G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on out- comes of clopidogrel treatment. N Engl J Med. 2010;363:1704 14. 291. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909 17. 292. O Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989 97. 293. AstraZeneca. Brilinta REMS Document. Available at: http://www.fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation- forPatientsandProviders/UCM264004.pdf. Accessed July 26, 2012. 294. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: 1045 57. 295. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 296. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel add- ed to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066 78. 297. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopido- grel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331 7. 298. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238 51. 299. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or tran- sient ischemic attack. Circulation. 2012;125:2914 21. 300. Verheugt FWA. Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke. Circulation. 2012;125:2821 3. 301. Shimada YJ, Nakra NC, Fox JT, et al. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intrave- nous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2012;109:624 8. 302. Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intra- venous administration of abciximab in patients with ST-segment eleva- tion myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Re- perfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial. Circulation. 2010;122:2709 17. 303. Thiele H, W hrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379:923 31. 304. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295:1519 30. 305. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open- label ATOLL trial. Lancet. 2011;378:693 703. 306. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-con- trolled clinical trial. Lancet. 1988;1:545 9. 307. EMERAS (Estudio Multic ntrico Estreptoquinasa Rep blicas de Am rica del Sur) Collaborative Group. Randomised trial of late throm- bolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767 72. 308. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349 60. 309. Late Assessment of Thrombolytic Efficacy (LATE) study with al- teplase 6 24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759 66. 310. Rossi P, Bolognese L. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction: Urochinasi per via Sistemica nell Infarto Miocardico (USIM) Collaborative Group. Am J Cardiol. 1991;68:585 92. 311. The I.S.A.M. Study Group. A prospective trial of Intravenous Streptoki- nase in Acute Myocardial infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986;314:1465 71. 312. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87:38 52. 313. Barrab s JA, Figueras J, Moure C, et al. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarc- tion. Circulation. 2003;108:814 9. 314. Bode C, Smalling RW, Berg G, et al; RAPID II Investigators. Random- ized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, acceler- ated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891 8. 315. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plas- minogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lan- cet. 1992;339:753 70. 316. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001;286:442 9. 317. The Global Use of Strategies to Open Occluded CoronaryArteries (GUS- TO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118 23. 318. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673 82. 319. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716 22. 320. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction:Anglo-Scan- dinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525 30. 321. Bonnefoy E, Godon P, Kirkorian G, et al. Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. Acta Cardiol. 2005;60:165 70. 322. Langer A, Goodman SG, Topol EJ, et al; LATE Study Investigators. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol. 1996;27:1327 32. 323. Terkelsen CJ, Lassen JF, N rgaard BL, et al. Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction? Heart. 2003;89:483 4. 324. The GUSTO Angiographic Investigators. The effects of tissue plasmino- gen activator, streptokinase, or both on coronary-artery patency, ventric- ular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615 22. Erratum in: N Engl J Med. 1994;330:516. 325. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001;103:2862 6. 326. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992;19:885 91. 327. Deleted in press. 328. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351 6. 329. Martin GV, Sheehan FH, Stadius M, et al. Intravenous streptokinase for acute myocardial infarction: effects on global and regional systolic func- tion. Circulation. 1988;78:258 66. 330. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet. 2005;366:1607 21. 331. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-seg- ment elevation. N Engl J Med. 2005;352:1179 89. 332. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfrac- tionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477 88. 333. Efficacy and safety of tenecteplase in combination with enoxaparin, ab- ciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605 13. 334. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001;104:648 52. 335. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunc- tive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002;105:1642 9. Erratum in: Circulation. 2002;105:2799. 336. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest. 1992;101:131S 9S. 337. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind Euro- pean Cooperative Study Group trial. Br Heart J. 1992;67:122 8. 338. Thompson PL, Aylward PE, Federman J, et al; for the National Heart Foundation of Australia Coronary Thrombolysis Group. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation. 1991;83:1534 42. 339. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarc- tion: results from the GUSTO-I trial. Circulation. 1996;93:870 8. 340. Fox KAA, Antman EM, Montalescot G, et al. The impact of renal dys- function on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49:2249 55. 341. Peters RJG, Joyner C, Bassand J-P, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a sub- group analysis of the OASIS-6 trial. Eur Heart J. 2008;29:324 31. 342. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855 63. 343. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993;21:1391 5. 344. Gibson CM, Murphy SA, Rizzo MJ, et al; Thrombolysis In Myocardial Infarction (TIMI) Study Group. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1999;99:1945 50. 345. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percu- taneous coronary intervention to long-term outcomes after throm- bolytic administration in acute myocardial infarction. Circulation. 2002;105:1909 13. 346. Sutton AGC, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST- segment elevation myocardial infarction: the Middlesbrough Early Re- vascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004;44:287 96. 347. Sutton AG, Campbell PG, Price DJ, et al. Failure of thrombolysis by streptokinase: detection with a simple electrocardiographic method. Heart. 2000;84:149 56. 348. Fernandez AR, Sequeira RF, Chakko S, et al. ST segment tracking for rapid determination of patency of the infarct-related artery in acute myo- cardial infarction. J Am Coll Cardiol. 1995;26:675 83. 349. de Lemos JA, Antman EM, Giugliano RP, et al; Thrombolysis in Myo- cardial Infarction (TIMI) 14 Investigators. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol. 2000;85:299 304. 350. Zeymer U, Schr der R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction: results of the an- giographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur Heart J. 2001;22:769 75. 351. Cooper HA, de Lemos JA, Morrow DA, et al. Minimal ST-segment de- viation: a simple, noninvasive method for identifying patients with a pat- ent infarction-related artery after fibrinolytic administration. Am Heart J. 2002;144:790 5. O Gara et al 2013 ACCF/AHA STEMI Guideline e411 352. Purcell IF, Newall N, Farrer M. Change in ST segment elevation 60 min- utes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changes. Heart. 1997;78:465 71. 353. Schr der R, Wegscheider K, Schr der K, et al. Extent of early ST seg- ment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombo- lytic regimens: a substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995;26:1657 64. 354. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190 2. 355. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758 68. 356. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue an- gioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST- segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422 30. 357. Collet J-P, Montalescot G, Le May M, et al. Percutaneous coronary inter- vention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326 35. 358. B hmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of im- mediate angioplasty versus ischemia-guided management after throm- bolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55:102 10. 359. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutane- ous coronary intervention after fibrinolysis vs. standard therapy in ST- segment elevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31:2156 69. 360. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angio- plasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705 18. 361. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Com- bined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559 68. 362. Fernandez-Avil s F, Alonso JJ, Castro-Beiras A, et al. Routine inva- sive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-seg- ment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364:1045 53. 363. White HD. Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrino- lysis. Circulation. 2008;118:219 22. 364. Appleton DL, Abbate A, Biondi-Zoccai GGL. Late percutaneous coro- nary intervention for the totally occluded infarct-related artery: a me- ta-analysis of the effects on cardiac function and remodeling. Catheter Cardiovasc Interv. 2008;71:772 81. 365. Danchin N, Coste P, Ferri res J, et al. Comparison of thrombolysis fol- lowed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myo- cardial infarction: data from the French registry on Acute ST-elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118:268 76. 366. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical out- comes associated with reinfarction following fibrinolytic administration in the Thrombolysis In Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7 16. 367. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet. 2002;359:1805 11. 368. Armstrong PW. A comparison of pharmacologic therapy with/with- out timely coronary intervention vs. primary percutaneous interven- tion early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530 8. 369. Le May MR,Wells GA, Labinaz M, et al. Combined angioplasty and phar- macological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005;46:417 24. 370. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immedi- ate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634 41. 370a.Granger CB. Who should have a routine early invasive approach after fibrinolytic therapy? Eur Heart J. 2011;32:1961-3. 371. Thiele H, Engelmann L, Elsner K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combi- nation-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26:1956 63. 372. Steg PG, Kerner A, Van de Werf F, et al. Impact of in-hospital revascu- larization on survival in patients with non-ST-elevation acute coronary syndrome and congestive heart failure. Circulation. 2008;118:1163 71. 373. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: obser- vations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494 9. 374. D Souza SP, Mamas MA, Fraser DG, et al. Routine early coronary angioplas- ty versus ischaemia-guided angioplasty after thrombolysis in acute ST-eleva- tion myocardial infarction: a meta-analysis. Eur Heart J. 2011;32:972 82. 375. Gupta M, Chang W-C, Van de Werf F, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J. 2003;24:1640 50. 376. Ioannidis JPA, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J. 2007;154:1065 71. 377. Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of oc- cluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187 94. 378. Wilson SH, Bell MR, Rihal CS, et al. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J. 2001;141:704 10. 379. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511 5. 380. Hochman JS, Reynolds HR, Dzav k V, et al. Long-term effects of per- cutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011;124:2320 8. 381. Jaski BE, Cohen JD, Trausch J, et al. Outcome of urgent percutaneous transluminal coronary angioplasty in acute myocardial infarction: com- parison of single-vessel versus multivessel coronary artery disease. Am Heart J. 1992;124:1427 33. 382. Muller DW, Topol EJ, Ellis SG, et al; Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Am Heart J. 1991;121:1042 9. 383. Corpus RA, House JA, Marso SP, et al. Multivessel percutaneous coro- nary intervention in patients with multivessel disease and acute myocar- dial infarction. Am Heart J. 2004;148:493 500. 384. Rigattieri S, Biondi-Zoccai G, Silvestri P, et al. Management of multives- sel coronary disease after ST elevation myocardial infarction treated by primary angioplasty. J Interv Cardiol. 2008;21:1 7. 385. Ntalianis A, Sels J-W, Davidavicius G, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274 81. 386. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARA- DIGM) trial. J Am Coll Cardiol. 1998;32:2003 10. 387. Ohman EM, Kleiman NS, Gacioch G, et al; IMPACT-AMI Investiga- tors. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose- ranging trial. Circulation. 1997;95:846 54. 388. Deleted in press. 389. Ronner E, van Domburg RT, van den Brand MJBM, et al. Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies: single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction. Eur Heart J. 2002;23:1529 37. 390. Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49:2238 46. 391. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease: long-term CASS experience. Circulation. 1995;91:2325 34. 392. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicat- ing acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry: SHould we emergently revascu- larize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36:1063 70. 393. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Prac- tice Guidelines. Circulation. 2011;124:e652 735. 394. Dalrymple-Hay MJ, Langley SM, Sami SA, et al. Should coronary artery bypass grafting be performed at the same time as repair of a post-infarct ventricular septal defect? Eur J Cardiothorac Surg. 1998;13:286 92. 395. Menon V, Webb JG, Hillis LD, et al. Outcome and profile of ventricu- lar septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry: SHould we emergently revas- cularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol. 2000;36:1110 6. wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry: Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol. 2000;36:1117 22. 397. Tavakoli R, Weber A, Vogt P, et al. Surgical management of acute mitral valve regurgitation due to post-infarction papillary muscle rupture. J Heart Valve Dis. 2002;11:20 5 398. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarc- tion: a report from the SHOCK Trial Registry: SHould we use emer- gently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol. 2000;36:1104 9. 399. Jacob M, Smedira N, Blackstone E, et al. Effect of timing of chronic pre- operative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation. 2011;123:577 83. 400. Kim JH-J, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J. 2008;156:886 92. 401. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672 84. 402. Nijjer SS, Watson G, Athanasiou T, et al. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J. 2011;32:2970 88. 403. Barker CM, Anderson HV. Acute coronary syndromes: don t bypass the clopidogrel. J Am Coll Cardiol. 2009;53:1973 4. 404. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes un- dergoing coronary artery bypass surgery: the ACUITY (Acute Catheter- ization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009;53:1965 72. 405. Bizzarri F, Scolletta S,Tucci E, et al. Perioperative use of tirofiban hydrochlo- ride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronaryarterybypassgrafting.JThoracCardiovascSurg.2001;122:1181 5. 406. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann Thorac Surg. 2000;70:866 71; discussion 871 2. 407. Shim JK, Choi YS, Oh YJ, et al. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion re- quirements in patients undergoing off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2007;134:59 64. 408. Woo YJ, Grand T, Valettas N. Off-pump coronary artery bypass grafting attenuates postoperative bleeding associated with preoperative clopido- grel administration. Heart Surg Forum. 2003;6:282 5. 409. Maltais S, Perrault LP, Do Q-B. Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: impact of discontinuation prior to surgery. Eur J Cardiothorac Surg. 2008;34:127 31. 410. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 502. Errata in: N Engl J Med. 2001;345:1716 and N Engl J Med. 2001;345:1506. 411. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combi- nation with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231 7. 412. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coro- nary artery bypass surgery. Crit Care Med. 2001;29:2271 5. 413. Firanescu CE, Martens EJ, Sch nberger JPAM, et al. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preop- erative treatment with clopidogrel: a prospective randomised controlled study. Eur J Cardiothorac Surg. 2009;36:856 62. 414. Chen ZM, Pan HC, ChenYP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet. 2005;366:1622 32. 415. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred be- ta-blockade following thrombolytic therapy in patients with acute myo- cardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422 37. 416. First International Study of Infarct Survival Collaborative Group. Ran- domised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57 66. 417. A randomized trial of propranolol in patients with acute myocardial in- farction, I: mortality results. JAMA. 1982;247:1707 14. 418. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocar- dial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. 419. Deleted in press. 420. Pfeffer MA, Braunwald E, Moy LA, et al; the SAVE Investigators. Ef- fect of captopril on mortality and morbidity in patients with left ventricu- lar dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669 77. 421. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial infarction: the AIRE Study in practice: Acute Infarction Ramipril Efficacy Study. Eur Heart J. 1994;15 Suppl B:20 5; discus- sion 26 30. 422. K ber L, Torp-Pedersen C, Carlsen JE, et al; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin- converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670 6. 423. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angio- tensin-converting enzyme inhibition therapy in acute myocardial infarc- tion: the healing and early afterload reducing therapy trial. Circulation. 1997;95:2643 51. 424. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricu- lar dysfunction, or both. N Engl J Med. 2003;349:1893 906. Erratum in: N Engl J Med. 2004;350:203. 425. Maggioni AP, Fabbri G. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opin Pharmacother. 2005;6:507 12. 426. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial in- farction. N Engl J Med. 2003;348:1309 21. Erratum in: N Engl J Med. 2003;348:2271. 427. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in random- ized trials. Circulation. 1998;97:2202 12. 428. Gruppo Italiano per lo Studio della Sopravvivenza nell infarto Miocar- dico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate sin- gly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115 22. 429. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669 85. 430. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: a report from the AIRE Study Investiga- tors. Eur Heart J. 1997;18:41 51. O Gara et al 2013 ACCF/AHA STEMI Guideline e413 431. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752 60. 432. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting- enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351:2058 68. 433. Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarc- tion complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009;11:1099 105. 434. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovas- cular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 45. 435. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. 436. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moder- ate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. Erratum in: N Engl J Med. 2006;354:778. 437. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001 9. 438. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 439. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a de- layed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307 16. 440. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711 8. 441. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581. htm. Accessed May 18, 2012. 442. Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density li- poprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin orAtorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarc- tion 22) analysis. J Am Coll Cardiol. 2008;52:914 20. 443. Lee KH, Jeong MH, Kim HM, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low- density lipoprotein cholesterol. J Am Coll Cardiol. 2011;58:1664 71. 444. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consen- sus document: use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation. 1999;99:168 77. Erratum in: J Am Coll Cardiol. 1999;34:1850. 445. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myo- cardial infarction and unstable angina: an overview. BMJ. 1989;299: 1187 92. 446. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326 31. 447. McNulty PH, King N, Scott S, et al. Effects of supplemental oxygen ad- ministration on coronary blood flow in patients undergoing cardiac cath- eterization. Am J Physiol Heart Circ Physiol. 2005;288:H1057 62. 448. Gibson CM, Pride YB, Aylward PE, et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment el- evation myocardial infarction treated with fibrinolytic therapy: an Ex- TRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009;27:11 7. 449. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarc- tion associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906 13. 450. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302 8. 451. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy- genase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633 44. 452. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448 54. 453. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treat- ment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031 7. 454. French JK, Feldman HA, Assmann SF, et al. Influence of thrombo- lytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J. 2003;146:804 10. 455. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141:933 9. 456. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003;108:951 7. 457. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra- aortic balloon pump counterpulsation, and their combination in cardio- genic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36:1123 9. 458. Sjauw KD, Engstr m AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30:459 68. 459. Ohman EM, Nanas J, Stomel RJ, et al. Thrombolysis and counterpulsa- tion to improve survival in myocardial infarction complicated by hypo- tension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis. 2005;19:33 9. 460. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associ- ated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24:828 37. 461. Dauerman HL, Goldberg RJ, Malinski M, et al. Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. Am J Cardiol. 2001;87:844 8. 462. Dauerman HL, Ryan TJ Jr, Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol. 2003;15:380 4. 463. Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular as- sist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57:688 96. 464. Thiele H, Smalling RW, Schuler GC. Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2007;28:2057 63. 465. De Backer D, Biston P, Devriendt J, et al. Comparison of dopa- mine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779 89. 466. Robalino BD, Whitlow PL, Underwood DA, et al. Electrocardiograph- ic manifestations of right ventricular infarction. Am Heart J. 1989; 118:138 44. 467. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/Ameri- can Heart Association Task Force on Practice Guidelines (ACC/AHA/ ASE Committee to Update the 1997 Guidelines for the Clinical Applica- tion of Echocardiography). Circulation. 2003;108:1146 62. 468. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med. 1994;330:1211 7. 469. Wellens HJ. The value of the right precordial leads of the electrocardio- gram. N Engl J Med. 1999;340:381 3. 470. Tanimoto T, Imanishi T, Kitabata H, et al. Prevalence and clinical sig- nificance of papillary muscle infarction detected by late gadolinium- enhanced magnetic resonance imaging in patients with ST-segment elevation myocardial infarction. Circulation. 2010;122:2281 7. 471. Yosefy C, Beeri R, Guerrero JL, et al. Mitral regurgitation after antero- apical myocardial infarction: new mechanistic insights. Circulation. 2011;123:1529 36. 472. Tepe NA, Edmunds LH Jr. Operation for acute postinfarction mi- tral insufficiency and cardiogenic shock. J Thorac Cardiovasc Surg. 1985;89:525 30. 473. Chen Q, Darlymple-Hay MJ, Alexiou C, et al. Mitral valve surgery for acute papillary muscle rupture following myocardial infarction. J Heart Valve Dis. 2002;11:27 31. 474. Kishon Y, Oh JK, Schaff HV, et al. Mitral valve operation in postinfarc- tion rupture of a papillary muscle: immediate results and long-term fol- low-up of 22 patients. Mayo Clin Proc. 1992;67:1023 30. 475. Fasol R, Lakew F, Wetter S. Mitral repair in patients with a ruptured papillary muscle. Am Heart J. 2000;139:549 54. 476. Nishimura RA, Gersh BJ, Schaff HV. The case for an aggressive surgical approach to papillary muscle rupture following myocardial infarction: from paradise lost to paradise regained. Heart. 2000;83:611 3. 477. Crenshaw BS, Granger CB, BirnbaumY, et al; GUSTO-I (Global Utiliza- tion of Streptokinase and TPA for Occluded Coronary Arteries) Trial In- vestigators. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101:27 32. 478. Pr tre R,Ye Q, Gr nenfelder J, et al. Operative results of repair of ven- tricular septal rupture after acute myocardial infraction. Am J Cardiol. 1999;84:785 8. 479. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ven- tricular septum after acute myocardial infarction and role of early surgi- cal intervention. Am J Cardiol. 1992;70:147 51. 480. Skillington PD, Davies RH, Luff AJ, et al. Surgical treatment for infarct-related ventricular septal defects: improved early results com- bined with analysis of late functional status. J Thorac Cardiovasc Surg. 1990;99:798 808. 481. Topaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of inva- sive and noninvasive diagnostic modalities in current management. Am J Med. 1992;93:683 8. 482. Westaby S, Parry A, Ormerod O, et al. Thrombolysis and postinfarction ventricular septal rupture. J Thorac Cardiovasc Surg. 1992;104:1506 9. 483. Muehrcke DD, Daggett WM Jr, Buckley MJ, et al. Postinfarct ventricular septal defect repair: effect of coronary artery bypass grafting.Ann Thorac Surg. 1992;54:876 82; discussion 882 883. 484. Birnbaum Y, Chamoun AJ, Anzuini A, et al. Ventricular free wall rup- ture following acute myocardial infarction. Coron Artery Dis. 2003;14: 463 70. 485. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 1996;27:1321 6. 486. Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Car- diol. 1990;16:359 67. 487. McMullan MH, Maples MD, Kilgore TL Jr, et al. Surgical experience with left ventricular free wall rupture. Ann Thorac Surg. 2001;71:1894 8; discussion 1898 9. 488. Newby KH, Thompson T, Stebbins A, et al; the GUSTO Investigators. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. Circulation. 1998;98:2567 73. 489. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associ- ated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779 89. 490. 2010 Advanced Cardiac Life Support Guidelines. Available at: http:// acls-algorithms.com/vfpulseless-vt. Accessed May 16, 2012. 491. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of im- plantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195 203. 492. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Ar- rest Study Hamburg). Am Heart J. 1994;127:1139 44. 493. Connolly SJ, Hallstrom AP, Cappato R, et al; for the AVID, CASH and CIDS studies: Antiarrhythmics vs Implantable Defibrillator study: Car- diac Arrest Study Hamburg: Canadian Implantable Defibrillator Study. Meta-analysis of the implantable cardioverter defibrillator secondary pre- vention trials. Eur Heart J. 2000;21:2071 8. 494. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investiga- tors. A comparison of antiarrhythmic-drug therapy with implantable defi- brillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. 495. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibril- lator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. 496. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008;117:e350 408. Erratum in: Circulation. 2009;120:e34 5. 497. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and out- comes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30:2019 28. 498. Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907 14. 499. Califf RM, White HD, Van de Werf F, et al; GUSTO-I Investigators. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation. 1996;94:1233 8. 500. Bloch Thomsen PE, Jons C, Raatikainen MJP, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Car- diac Arrhythmias and Risk Stratification After Acute Myocardial Infarc- tion (CARISMA) study. Circulation. 2010;122:1258 64. 501. Fuster V, Ryd n LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the Ameri- can College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology. Circulation. 2011;123:e269 367. 502. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the manage- ment of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369 429. Erratum in: Eur Heart J. 2011;32:1172. 503. Deleted in press. 504. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardio- vascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S729-67. Erratum in: Circulation. 2011;123:e236. 505. Hreybe H, Saba S. Location of acute myocardial infarction and associ- ated arrhythmias and outcome. Clin Cardiol. 2009;32:274 7. 506. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRU- SADE Quality Improvement Initiative. Am Heart J. 2005;149:1043 9. 507. Newby KH, Pisan E, Krucoff MW, et al. Incidence and clinical rele- vance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. Circulation. 1996;94:2424 8. 508. Petrina M, Goodman SG, Eagle KA. The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: cur- rent status in an era of revascularization and reperfusion. Am Heart J. 2006;152:11 8. 509. Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspi- rin, indomethacin, prednisone, and spontaneous resolution. Am Heart J. 1981;101:750 3. 510. Bulkley BH, Roberts WC. Steroid therapy during acute myocardial in- farction: a cause of delayed healing and of ventricular aneurysm. Am J Med. 1974;56:244 50. 511. Silverman HS, Pfeifer MP. Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial in- farction. Am J Cardiol. 1987;59:363 4. 512. Imazio M, Negro A, Belli R, et al. Frequency and prognostic significance of pericarditis following acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol. 2009;103:1525 9. O Gara et al 2013 ACCF/AHA STEMI Guideline e415 513. Orsinelli DA, Pearson AC. Usefulness of transesophageal echocardiog- raphy to screen for left atrial thrombus before elective cardioversion for atrial fibrillation. Am J Cardiol. 1993;72:1337 9. 514. Wall TC, Califf RM, Harrelson-Woodlief L, et al; the TAMI Study Group. Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. Am J Cardiol. 1990;66:1418 21. 515. Patel MR, Meine TJ, Lindblad L, et al. Cardiac tamponade in the fibrino- lytic era: analysis of >100,000 patients with ST-segment elevation myo- cardial infarction. Am Heart J. 2006;151:316 22. 516. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26:549 57. 517. Gueret P, Khalife K, Jobic Y, et al. Echocardiographic assessment of the incidence of mechanical complications during the early phase of myo- cardial infarction in the reperfusion era: a French multicentre prospective registry. Arch Cardiovasc Dis. 2008;101:41 7. 518. L pez-Send n J, Gurfinkel EP, Lopez de Sa E, et al. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31:1449 56. 519. Figueras J, Juncal A, Carballo J, et al. Nature and progression of pericar- dial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture. Am Heart J. 2002;144:251 8. 520. Figueras J, Barrab s JA, Serra V, et al. Hospital outcome of moderate to severe pericardial effusion complicating ST-elevation acute myocardial infarction. Circulation. 2010;122:1902 9. 521. Andreotti F, Testa L, Biondi-Zoccai GGL, et al. Aspirin plus warfa- rin compared to aspirin alone after acute coronary syndromes: an up- dated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519 26. 522. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Prac- tice Guidelines. Chest. 2012;141:e531S e575S. 523. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary preven- tion of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e637S 68S. Erra- tum in: Chest. 2012;141:1129. 524. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/ or undergoing coronary stenting: executive summary: a Consensus Docu- ment of the European Society of Cardiology Working Group on Throm- bosis. Eur Heart J. 2010;31:1311 8. 525. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: an- tithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North-American perspective. Thromb Haemost. 2011;106:572 84. 526. Turpie AGG, Chin BSP, Lip GYH. Venous thromboembolism: patho- physiology, clinical features, and prevention. BMJ. 2002;325:887 90. 527. Ng TMH, Tsai F, Khatri N, et al. Venous thromboembolism in hospi- talized patients with heart failure: incidence, prognosis, and prevention. Circ Heart Fail. 2010;3:165 73. 528. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis compar- ing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing fre- quency. Arch Intern Med. 2000;160:181 8. 529. Matsuo T, Tomaru T, Kario K, et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute cor- onary syndrome. Thromb Res. 2005;115:475 81. 530. Ohman EM, Granger CB, Rice L, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a reg- istry of prolonged heparin use and thrombocytopenia among hospital- ized patients with and without cardiovascular disease: the Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. J Thromb Thrombolysis. 2005;19:11 9. 531. Crespo EM, Oliveira GBF, Honeycutt EF, et al. Evaluation and manage- ment of thrombocytopenia and suspected heparin-induced thrombocyto- penia in hospitalized patients: the ComplicationsAfterThrombocytopenia Caused by Heparin (CATCH) Registry. Am Heart J. 2009;157:651 7. 532. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with war- farin. Am J Med. 1998;105:91 9. 533. S rensen R, Hansen ML,Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospec- tive analysis of nationwide registry data. Lancet. 2009;374:1967 74. arin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e495S e530S. 535. Rao SV, O Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200 6. 536. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocar- dial infarction? Circulation. 2007;116:2793 801. 537. Giugliano RP, Giraldez RR, Morrow DA, et al. Relations between bleed- ing and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010;31:2103 10. 538. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocar- dial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532 9. Erratum in: JAMA. 2008;299:2390. 539. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfu- sion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555 62. 540. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and compli- cations after cardiac surgery. N Engl J Med. 2008;358:1229 39. 541. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction under- going primary angioplasty: results from the HORIZONS-AMI (Harmo- nizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2009;54:1438 46. 542. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned gly- coprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853 63. Erratum in: JAMA. 2003;289:1638. 543. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108 16. Erratum in: JAMA. 2006;295:628. 544. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleed- ing on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774 82. 545. Rao SV, O Grady K, Pieper KS, et al. A comparison of the clinical im- pact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809 16. 546. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362 8. 547. Mathews R, Peterson ED, Chen AY, et al. In-hospital major bleeding dur- ing ST-elevation and non-ST-elevation myocardial infarction care: deri- vation and validation of a model from the ACTION Registry-GWTG. Am J Cardiol. 2011;107:1136 43. 548. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients under- going percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Car- diovasc Interv. 2009;2:222 9. 549. Kadakia MB, Desai NR, Alexander KP, et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry-GWTG (National Cardio- vascular Data Registry Acute Coronary Treatment and Intervention Out- comes Network Registry Get With the Guidelines). JACC Cardiovasc Interv. 2010;3:1166 77. 550. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarc- tion 38 (TRITON-TIMI 38). Circulation. 2011;123:2681 9. 551. H bert PC, Wells G, Blajchman MA, et al; Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A mul- ticenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409 17. Erratum in: N Engl J Med. 1999;340:1056. 552. Aronson D, Dann EJ, Bonstein L, et al. Impact of red blood cell transfu- sion on clinical outcomes in patients with acute myocardial infarction. Am J Cardiol. 2008;102:115 9. 553. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleed- ing in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556 66. 554. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:257S 98S. 555. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombi- nant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127 37. 556. Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol. 2008;65:1313 8. 557. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing per- cutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936 45. 558. Rao SV, Ou F-S, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardio- vasc Interv. 2008;1:379 86. 559. Agostoni P, Biondi-Zoccai GGL, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interven- tional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349 56. 560. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial ac- cess site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019 25. 561. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coro- nary angiography and intervention in patients with acute coronary syn- dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409 20. Errata in: Lancet. 2011;377:1408 and Lancet. 2011;378:30. 562. Patel MR, Jneid H, Derdeyn CP, et al. Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association. Circulation. 2010;122:1882 93. Erratum in: Circula- tion. 2010;122:e507. 563. Marso SP, Amin AP, House JA, et al. Association between use of bleed- ing avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303:2156 64. 564. Koreny M, Riedm ller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac cathe- terization: systematic review and meta-analysis. JAMA. 2004;291:350 7. 565. Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complica- tions after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv. 2008;1:202 9. 566. Dauerman HL, Rao SV, Resnic FS, et al. Bleeding avoidance strategies: consensus and controversy. J Am Coll Cardiol. 2011;58:1 10. 567. Kosiborod M, McGuire DK. Glucose-lowering targets for patients with cardiovascular disease: focus on inpatient management of patients with acute coronary syndromes. Circulation. 2010;122:2736 44. 568. Pinto DS, Skolnick AH, Kirtane AJ, et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment eleva- tion myocardial infarction. J Am Coll Cardiol. 2005;46:178 80. 569. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in pa- tients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018 27. 570. Finfer S, Chittock DR, Su SY-S, et al. Intensive versus conventional glu- cose control in critically ill patients. N Engl J Med. 2009;360:1283 97. 571. Mehta SR,Yusuf S, D az R, et al. Effect of glucose-insulin-potassium in- fusion on mortality in patients with acute ST-segment elevation myocar- dial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437 46. 572. van der Horst ICC, Zijlstra F, van t Hof AWJ, et al. 